THE LEVELS OF IL-6, CRP, and LDH IN THE VITREOUS HUMOUR OF DIABETIC RETINOPATHY PATIENTS.
Article Sidebar
Main Article Content
Abstract
Introduction: Diabetic retinopathy (DR) is a significant complication of diabetes mellitus (DM) and remains a leading cause of vision loss among working-age individuals. Level of inflammatory biomarkers rise in DR. Main focus on Interleukin-6(IL-6), C-Reactive Protein (CRP) and Lactate Dehydrogenase (LDH) as IL-6 induces excess production of VEGF, CRP has both pro-inflammatory and anti-inflammatory properties whereas, LDH acts through oxidation process on pyruvate to be converted into lactate. Altered lactate levels reflect changes in glucose metabolism rates or pyruvate levels.
Methods: Prospective hospital-based cross-sectional study was carried out on diagnosed cases of Diabetic Retinopathy at a tertiary care centre. Selection of 50 patients was done as per inclusion criteria and exclusion criteria.
Results: Among NPDR patients, Mean of IL-6 levels was 23.59 ± 19.02, LDH was 99.46 ± 51.17 CRP was 0.49 ± 0.30 whereas in PDR patients, Mean of IL-6 was 58.91 ± 26.50, LDH was 202.5 ± 63.93 and CRP was 0.93 ± 0.33 showing 2-fold raised in PDR patients.
Conclusion: Our study emphasizes the crucial role of inflammatory biomarkers in the pathogenesis of diabetic retinopathy. The elevated levels of IL-6, LDH, and CRP in vitreous humor samples from PDR patients compared to NPDR patients indicate the activation of an inflammatory pathway during the disease’s progression. This research paves the way for further investigations into targeted therapies that can modulate these inflammatory mediators, potentially improving the prognosis of diabetic retinopathy.
Keywords
diabetes, vitreous, IL-6, CRP, LDH
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
References
2. P. N. Bishop, “Structural macromolecules and supram-olecular organisation of the vitreous gel,” Progress in Retinal and Eye Research, vol. 19, no. 3, pp. 323-344, 2000.
3. J. Sebag, “The vitreous,” in Adlers Physiology of the Eye, W. Hart, Ed., pp. 268-347, Mosby St. Louis, 1992.
4. J. N. Ulrich, M. Spannagl, A. Kampik, and A. Gandorfer, Components of the fibrinolytic system in the vitreous body in patients with vitreoretinal disorders,” Clinical and Experimental Ophthalmology, vol. 36, no. 5, pp. 431-436, 2008.
5. P. N. Bishop, M. Takanosu, M. Le Goff, and R. Mayne, The role of the posterior ciliary body in the biosynthesis of vitreous humour,” Eye, vol. 16, no. 4, pp. 454-460, 2002.
6. C. W. Wu, J. L. Sauter, P. K. Johnson, C. D. Chen, and T. W. Olsen, “Identification and localization of major (00592-015 soluble vitreous proteins in human ocular 1832 tissue,” American Journal of Ophthalmology, vol. 137, no. 4, pp. 655-661, 2004.
7. T. Shitama, H. Hayashi, S. Noge et al., “Proteome profiling of vitreoretinal diseases by cluster analysis,” Proteomics-Clinical Applications, vol. 2, no. 9, pp. 1265-1280, 2008.
8. Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring HarbPerspect Biol. 2014 Sep 4 ; 6 (10) : a016295. doi: 10.1101/cshperspect.a016295. PMID: 25190079; PMCID: PMC4176007.
9. Jungen MJ, Ter Meulen BC, van Osch T, Weinstein HC, Ostelo RWJG. Inflammatory biomarkers in patients with sciatica: a systematic review. BMC MusculoskeletDisord. 2019 Apr 09;20(1):156. [PMC free article] [PubMed].
10. Kramer NE, Cosgrove VE, Dunlap K, Subramaniapillai M, McIntyre RS, Suppes T. A clinical model for identifying an inflammatory phenotype in mood disorders. J Psychiatr Res. 2019 Jun;113:148-158. [PubMed].
11. Joshi SP, et al. Comparison between salivary and serum lactatedehydrogenase levels in patients with oral leukoplakia,and oral squamous cell carcinoma - A pilot study. InternationalJournal of Oral and Maxillofacial Pathology. 2012;3(4):7–12. [Google Scholar]
12. Acharya S, Kale J, Hallikeri K, Desai A. Prognostic Significance of Preoperative Salivary and Serum LactateDehydrogenase in Oral Squamous Cell Carcinoma Patients. Acta Scientific Cancer Biology. 2018;2(8):2–10. [Google Scholar]
13. Sivaramkrishnan M, et al. Evaluation of lactate dehydrogenaseenzyme activity in saliva and serum of oral submucousfibrosis patients. Journal of Oral Pathology Medicine. 2015;44(6):449–452. [PubMed] [Google Scholar]
14. Alkhatib AJ, Alrakaf NASM. Lactate Dehydrogenase: Physiological Roles and Clinical Implications. Am J Biomed Sci and Res. 2019;3(5) doi: 10.34297/AJBSR.2019.03.000705. [CrossRef] [Google Scholar]
15. Garcia Alvarez M, Marik P, Bellomo R (2014) Sepsis-associated hyperlactatemia. Crit Care 18(5): 503.
16. Ozawa GY, Bearse MA Jr, Adams AJ. Male-female differences in diabetic retinopathy? Curr Eye Res. 2015 Feb;40(2):234-46. Doi: 10.3109/02713683.2014.958500. Epub 2014 Dec 29. PMID: 25545999.
17. Deuchler S, Schubert R, Singh P, Chedid A, Brui N, Kenikstul N, Kohnen T, Ackermann H, Koch F. Vitreous expression of cytokines and growth factors in patients with diabetic retinopathy-An investigation of their expression based on clinical diabetic retinopathy grade. PLoS One. 2021 May 19;16(5):e0248439. Doi: 10.1371/journal.pone.0248439. PMID: 34010297; PMCID: PMC8133486.
18. Mjwara M, Khan M, Kruse CH, Sibanda W, Connolly C. Significance of HbA1c levels in diabetic retinopathy extremes in South Africa. S Afr Med J. 2021 Sep 2;111(9):886-890. PMID: 34949254.
19. Chernykh VV, Varvarinsky EV, Smirnov EV, Chernykh DV, Trunov AN. Proliferative and inflammatory factors in the vitreous of patients with proliferative diabetic retinopathy. Indian J Ophthalmol. 2015 Jan ; 63 (1) : 33-6. Doi: 10.4103/0301-4738.151464. PMID: 25686060; PMCID: PMC4363955.
20. Boss JD, Singh PK, Pandya HK, Tosi J, Kim C, Tewari A, Juzych MS, Abrams GW, Kumar A. Assessment of Neurotrophins and Inflammatory Mediators in Vitreous of Patients With Diabetic Retinopathy. Invest Ophthalmol Vis Sci. 2017 Oct 1;58(12):5594-5603. Doi: 10.1167/iovs.17-21973. PMID: 29084332; PMCID: PMC5667399.
21. Urbancic M, Korosec P, Flezar M, Globocnik Petrovič M. Diabetic retinopathy as a subclinical inflammation: Vitreous and serum cytokine analysis. Zdrav Vestn. 2020;89(5–6):243–54.
22. Platania CBM, Giurdanella G, Di Paola L, Leggio GM, Drago F, Salomone S, Bucolo C. P2X7 receptor antagonism: Implications in diabetic retinopathy. Biochem Pharmacol. 2017 Aug 15;138:130-139. Doi: 10.1016/j.bcp.2017.05.001. Epub 2017 May 4. PMID: 28479300.
23. Nalini M, Raghavulu BV, Annapurna A, Avinash P, Chandi V, Swathi N, Wasim. Correlation of various serum biomarkers with the severity of diabetic retinopathy. Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S451-S454. Doi: 10.1016/j.dsx.2017.03.034. Epub 2017 Apr 8. PMID: 28420575.
24. Loporchio, D.F.; Tam, E.K.; Cho, J.; Chung, J.; Jun, G.R.; Xia,W.; Fiorello, M.G.; Siegel, N.H.; Ness, S.; Stein, T.D.; et al. Cytokine Levels in Human Vitreous in Proliferative Diabetic Retinopathy. Cells 2021, 10, 1069. https://doi.org/10.3390 /cells10051069.
25. Lobo A, Lightman S. Vitreous aspiration needle tap in the diagnosis of intraocular inflammation. Ophthalmology. 2003 Mar;110(3):595-9. Doi: 10.1016/S0161-6420(02)01895-X. PMID: 12623828.
26. Hamzah Khalaf; Victor H Gonzalez : Case Series Report of Safety of Serial Vitreous Needle Taps in Patients with Proliferative Diabetic Retinopathy (PDR) and Central Retinal Vein Occlusion (CRVO). June 2017 ; Volume 58, Issue 8.